8-K Announcements
2Material company update
Feb 27, 2026·SEC
Material company update
Feb 26, 2026·SEC
Atrium Therapeutics, Inc.(RNA)Earnings, Financials & Key Ratios
RNA•NASDAQ
Price updated Jun 15, 2026
AboutAvidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Show more
- Revenue$19M+70.9%
- EBITDA-$76M+79.7%
- Net Income-$77M+76.2%
- EPS (Diluted)-4.48-55.0%
- Gross Margin100%
- EBITDA Margin-410.84%+88.1%
- Operating Margin-412.58%+88.1%
- Net Margin-411.88%+86.1%
- ROE-9.4%+71.9%
- ROIC-9.99%+73.0%
- Debt/Equity0.02+271.2%
RNA Key Insights
Atrium Therapeutics, Inc. (RNA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 22.4%
- ✓Share count reduced 84.7% through buybacks
- ✓Trading at only 1.1x book value
✗Weaknesses
- ✗Profits declining 11.6% over 5 years
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 5 (bottom 5%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when RNA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RNA Price & Volume
Atrium Therapeutics, Inc. (RNA) stock price & volume — 10-year historical chart
Loading chart...
RNA Growth Metrics
Atrium Therapeutics, Inc. (RNA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years22.36%
3 Years26.38%
TTM312.41%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-7.38%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-71.1%
Return on Capital
10 Years-31.36%
5 Years-31.49%
3 Years-29.39%
Last Year-9.02%
RNA Recent Earnings
Atrium Therapeutics, Inc. (RNA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 14, 2026EPS
$0.97
Est $1.05
+7.6%
Revenue
$20M
Est $2M
+881.8%
Q2 2026
Mar 2, 2026EPS
$1.70
Est $1.24
-37.1%
Revenue
$859,000
Est $2M
-59.4%
Q1 2026
Feb 26, 2026EPS
$0.61
Est $1.24
+50.8%
Revenue
$2M
Est $2M
+6.0%
Q1 2026
Feb 23, 2026EPS
$1.59
Est $1.32
-20.5%
Revenue
$860,000
Est $2M
-56.6%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.97vs $1.05+7.6% | $20Mvs $2M+881.8% |
| Q2 2026 | Mar 2, 2026 | $1.70vs $1.24-37.1% | $859,000vs $2M-59.4% |
| Q1 2026 | Feb 26, 2026 | $0.61vs $1.24+50.8% | $2Mvs $2M+6.0% |
| Q1 2026 | Feb 23, 2026 | $1.59vs $1.32-20.5% | $860,000vs $2M-56.6% |
Based on last 12 quarters of dataView full earnings history →
RNA Peer Comparison
Atrium Therapeutics, Inc. (RNA) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SRPT | 1.66B | 15.77 | -2.21 | 15.58% | 2.98% | 4.89% | 0.91 | |
 MDWD | 151.53M | 13.95 | -6.64 | -16.14% | -180.3% | -67.22% | 0.20 | |
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 RARE | 2.5B | 25.38 | -4.35 | 20.13% | -91.03% | -6.08% | ||
 BMRN | 10.7B | 55.65 | 30.92 | 12.87% | 8.29% | 4.41% | 0.11 | |
 ALNY | 38.4B | 287.80 | 123.52 | 65.19% | 13.46% | 98.29% | 1.62 | |
 IONS | 12.22B | 73.96 | -31.08 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ARWR | 10.87B | 77.15 | -6323.77 | 232.58% | -48.38% | -55.09% | 0.73 |
Compare RNA vs Peers
Atrium Therapeutics, Inc. (RNA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RNA Income Statement
Atrium Therapeutics, Inc. (RNA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 379K | 2.32M | 6.79M | 9.33M | 9.22M | 9.56M | 10.9M | 18.62M | 36.82M |
Revenue Growth % | - | 511.87% | 192.67% | 37.41% | -1.09% | 3.64% | 13.99% | 70.85% | 312.41% |
Cost of Goods Sold | 8.44M | 0 | 37.6M | 101.18M | 1.39M | 2.1M | 0 | 0 | 138.28M |
COGS % of Revenue | 2225.86% | - | 554.03% | 1084.95% | 15.04% | 21.98% | - | - | - |
Gross Profit | -8.06M▲ 0% | 2.32M▲ 128.8% | -30.82M▼ 1428.8% | -91.86M▼ 198.1% | 7.84M▲ 108.5% | 7.46M▼ 4.8% | 10.9M▲ 46.1% | 18.62M▲ 70.9% | -101.46M▲ 0% |
Gross Margin % | -2125.86% | 100% | -454.03% | -984.95% | 84.96% | 78.02% | 100% | 100% | -275.59% |
Gross Profit Growth % | - | 128.78% | -1428.81% | -198.09% | 108.53% | -4.82% | 46.09% | 70.85% | - |
Operating Expenses | 10.88M | 19.65M | 13.46M | 26.2M | 186.75M | 243.06M | 389.83M | 95.43M | 323.8M |
OpEx % of Revenue | 2869.92% | 847.39% | 198.35% | 280.88% | 2024.61% | 2542.44% | 3577.43% | 512.58% | - |
Selling, General & Admin | 2.44M | 5.11M | 13.46M | 26.2M | 37.73M | 54.19M | 86.24M | 41.68M | 133.7M |
SG&A % of Revenue | 644.06% | 220.44% | 198.35% | 280.88% | 409.07% | 566.84% | 791.41% | 223.85% | - |
Research & Development | 8.44M | 14.54M | 37.6M | 101.18M | 150.4M | 190.97M | 303.59M | 53.76M | 328.23M |
R&D % of Revenue | 2225.86% | 626.95% | 554.03% | 1084.95% | 1630.57% | 1997.57% | 2786.02% | 288.73% | - |
Other Operating Expenses | 0 | 0 | -37.6M | -101.18M | -1.39M | -2.1M | 0 | 0 | -1000K |
Operating Income | -10.5M▲ 0% | -17.33M▼ 65.1% | -44.28M▼ 155.5% | -118.05M▼ 166.6% | -178.91M▼ 51.6% | -235.6M▼ 31.7% | -378.94M▼ 60.8% | -76.81M▲ 79.7% | -425.26M▲ 0% |
Operating Margin % | -2769.92% | -747.39% | -652.38% | -1265.83% | -1939.65% | -2464.41% | -3477.43% | -412.58% | -1155.1% |
Operating Income Growth % | - | -65.1% | -155.46% | -166.62% | -51.56% | -31.68% | -60.84% | 79.73% | - |
EBITDA | -10.12M | -16.98M | -43.9M | -117.41M | -177.53M | -233.5M | -376.16M | -76.49M | -423.12M |
EBITDA Margin % | -2668.87% | -732.38% | -646.88% | -1258.97% | -1924.61% | -2442.44% | -3451.96% | -410.84% | -1149.28% |
EBITDA Growth % | - | -67.91% | -158.5% | -167.43% | -51.2% | -31.53% | -61.1% | 79.67% | 1.68% |
D&A (Non-Cash Add-back) | 383K | 348K | 373K | 639K | 1.39M | 2.1M | 2.78M | 323K | 2.14M |
EBIT | -10.5M | -17.35M | -44.15M | -118.05M | -178.91M | -235.6M | -378.94M | -76.81M | -410.9M |
Net Interest Income | -718K | -7.39M | -3K | 104K | 4.97M | 23.97M | 56.88M | 0 | 29.22M |
Interest Income | 0 | 0 | 206K | 104K | 4.97M | 23.97M | 56.88M | 0 | 29.22M |
Interest Expense | 718K | 7.39M | 209K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -718K | -7.4M | -78K | 42K | 4.92M | 23.38M | 56.63M | -12K | 28.84M |
Pretax Income | -11.22M▲ 0% | -24.73M▼ 120.5% | -44.35M▼ 79.3% | -118.01M▼ 166.1% | -174M▼ 47.4% | -212.22M▼ 22.0% | -322.3M▼ 51.9% | -76.83M▲ 76.2% | -396.43M▲ 0% |
Pretax Margin % | -2959.37% | -1066.58% | -653.53% | -1265.38% | -1886.33% | -2219.87% | -2957.71% | -412.64% | -1076.77% |
Income Tax | 718K | 0 | 0 | 0 | 0 | 0 | 0 | -142K | 34K |
Effective Tax Rate % | -6.4% | 0% | 0% | 0% | 0% | 0% | 0% | 0.18% | -0.01% |
Net Income | -11.93M▲ 0% | -24.73M▼ 107.3% | -44.35M▼ 79.3% | -118.01M▼ 166.1% | -174M▼ 47.4% | -212.22M▼ 22.0% | -322.3M▼ 51.9% | -76.68M▲ 76.2% | -396.46M▲ 0% |
Net Margin % | -3148.81% | -1066.58% | -653.53% | -1265.38% | -1886.33% | -2219.87% | -2957.71% | -411.88% | -1076.87% |
Net Income Growth % | - | -107.26% | -79.33% | -166.06% | -47.44% | -21.97% | -51.87% | 76.21% | -7.38% |
Net Income (Continuing) | -11.22M | -24.73M | -44.35M | -118.01M | -174M | -212.22M | -322.3M | -76.68M | -396.46M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.58▲ 0% | -0.86▼ 48.3% | -2.05▼ 138.4% | -2.85▼ 39.0% | -3.34▼ 17.2% | -2.91▲ 12.9% | -2.89▲ 0.7% | -4.48▼ 55.0% | -23.18▲ 0% |
EPS Growth % | - | -48.28% | -138.37% | -39.02% | -17.19% | 12.87% | 0.69% | -55.02% | -71.1% |
EPS (Basic) | -0.58 | -0.86 | -2.05 | -2.85 | -3.34 | -2.91 | -2.89 | -4.48 | - |
Diluted Shares Outstanding | 20.68M | 37.51M | 21.66M | 41.43M | 52.16M | 73.01M | 111.58M | 17.11M | 17.11M |
Basic Shares Outstanding | 20.68M | 37.51M | 21.66M | 41.43M | 52.16M | 73.01M | 111.58M | 17.11M | 17.11M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
RNA Balance Sheet
Atrium Therapeutics, Inc. (RNA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 3.24M | 95.68M | 331.68M | 411.14M | 622.94M | 611.31M | 1.54B | 272.85M | 285.56M |
Cash & Short-Term Investments | 3.09M | 94.58M | 328.14M | 405.54M | 610.73M | 595.35M | 1.5B | 270M | 267.85M |
Cash Only | 3.09M | 94.58M | 321.46M | 320.45M | 340.4M | 185.08M | 219.87M | 270M | 267.85M |
Short-Term Investments | 0 | 0 | 6.68M | 85.09M | 270.33M | 410.27M | 1.28B | 0 | 0 |
Accounts Receivable | 0 | 0 | 1.2M | 900K | 3.88M | 8.62M | 28.22M | 0 | 15M |
Days Sales Outstanding | - | - | 64.54 | 35.22 | 153.34 | 329.23 | 945.31 | - | 58.34 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 152K | 0 | 0 | 0 | 0 | 0 | 0 | 1.31M | 138K |
Total Non-Current Assets | 740K | 1.23M | 2.22M | 16.44M | 15.86M | 17.25M | 21.61M | 5.51M | 6.79M |
Property, Plant & Equipment | 702K | 631K | 1.92M | 15.59M | 15.01M | 16.65M | 18.29M | 5.51M | 6.38M |
Fixed Asset Turnover | 0.54x | 3.68x | 3.53x | 0.60x | 0.61x | 0.57x | 0.60x | 3.38x | 3.43x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.21M |
Other Non-Current Assets | 38K | 600K | 298K | 850K | 849K | 596K | 3.32M | 0 | 0 |
Total Assets | 3.98M▲ 0% | 96.91M▲ 2333.6% | 333.9M▲ 244.6% | 427.58M▲ 28.1% | 638.8M▲ 49.4% | 628.55M▼ 1.6% | 1.56B▲ 148.8% | 278.35M▼ 82.2% | 292.36M▲ 0% |
Asset Turnover | 0.10x | 0.02x | 0.02x | 0.02x | 0.01x | 0.02x | 0.01x | 0.07x | 0.07x |
Asset Growth % | - | 2333.63% | 244.56% | 28.06% | 49.4% | -1.6% | 148.81% | -82.2% | -243.65% |
Total Current Liabilities | 4.62M | 10.24M | 14.59M | 29.66M | 51.91M | 80.68M | 98.02M | 41.8M | 21.91M |
Accounts Payable | 1.56M | 2.31M | 7.75M | 2.81M | 4.64M | 8.81M | 8.46M | 4.4M | 807K |
Days Payables Outstanding | 67.71 | - | 75.18 | 10.12 | 1.22K | 1.53K | - | - | 6.32 |
Short-Term Debt | 2.75M | 2.77M | 0 | 0 | 0 | 0 | 0 | 0 | 2.68M |
Deferred Revenue (Current) | 0 | 3.84M | 0 | 0 | 5.04M | 28.36M | 20.99M | 21.64M | 63.64M |
Other Current Liabilities | 305K | 0 | 3.69M | 4.86M | 11.19M | 14.34M | 3.66M | 3.15M | 6.98M |
Current Ratio | 0.70x | 9.35x | 22.74x | 13.86x | 12.00x | 7.58x | 15.73x | 6.53x | 13.04x |
Quick Ratio | 0.70x | 9.35x | 22.74x | 13.86x | 12.00x | 7.58x | 15.73x | 6.53x | 13.04x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | 52.03 |
Total Non-Current Liabilities | 40.49M | 152.03M | 13.09M | 16.49M | 8.82M | 47.11M | 40.92M | 29.27M | 36.35M |
Long-Term Debt | 7.58M | 1.77M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 393K | 938K | 9.96M | 7.58M | 6.21M | 2.96M | 0 | 1.52M |
Deferred Tax Liabilities | 0 | 134.72M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 32.92M | 45K | 12.15M | 6.53M | 0 | 0 | 0 | 574K | 0 |
Total Liabilities | 45.11M | 162.26M | 27.68M | 46.15M | 60.73M | 127.79M | 138.94M | 71.07M | 58.26M |
Total Debt | 10.32M | 4.94M | 938K | 11.73M | 10.69M | 9.85M | 6.8M | 3.67M | 2.68M |
Net Debt | 7.23M | -89.64M | -320.52M | -308.72M | -329.71M | -175.23M | -213.07M | -266.33M | -265.17M |
Debt / Equity | - | - | 0.00x | 0.03x | 0.02x | 0.02x | 0.00x | 0.02x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.63x |
Interest Coverage | -14.62x | -2.35x | -211.22x | - | - | - | - | - | - |
Total Equity | -41.13M▲ 0% | -65.36M▼ 58.9% | 306.22M▲ 568.5% | 381.43M▲ 24.6% | 578.08M▲ 51.6% | 500.76M▼ 13.4% | 1.42B▲ 184.6% | 207.29M▼ 85.5% | 234.1M▲ 0% |
Equity Growth % | - | -58.91% | 568.54% | 24.56% | 51.55% | -13.37% | 184.56% | -85.45% | -256% |
Book Value per Share | -1.99 | -1.74 | 14.14 | 9.21 | 11.08 | 6.86 | 12.77 | 12.11 | 13.69 |
Total Shareholders' Equity | -41.13M | -65.36M | 306.22M | 381.43M | 578.08M | 500.76M | 1.42B | 207.29M | 234.1M |
Common Stock | 426K | 1K | 4K | 5K | 7K | 8K | 12K | 17K | 16K |
Retained Earnings | -41.55M | -22.18M | -66.54M | -184.55M | -358.54M | -570.76M | -893.07M | 0 | 12.13M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -33.12M | -134.72M | -5K | -187K | -2.7M | 125K | 2.9M | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RNA Cash Flow Statement
Atrium Therapeutics, Inc. (RNA) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -9.65M | 2.49M | -37.12M | -94.81M | -136.27M | -119.06M | -300.87M | -41.13M | -406.23M |
Operating CF Margin % | -2547.49% | 107.37% | -546.88% | -1016.65% | -1477.32% | -1245.44% | -2761.04% | -220.91% | - |
Operating CF Growth % | - | 125.79% | -1590.64% | -155.44% | -43.72% | 12.63% | -152.7% | 86.33% | -189.4% |
Net Income | -11.22M | -24.73M | -44.35M | -118.01M | -174M | -212.22M | -322.3M | -49.5M | -396.46M |
Depreciation & Amortization | 383K | 348K | 373K | 639K | 1.39M | 2.1M | 2.78M | 323K | -6.49M |
Stock-Based Compensation | 60K | 406K | 4.31M | 17.06M | 27.14M | 38.22M | 51.36M | 7.68M | 40.23M |
Deferred Taxes | 0 | 0 | 84K | 0 | 0 | 0 | 0 | -142K | 34K |
Other Non-Cash Items | 447K | 7.11M | 139K | 163K | -615K | -8.3M | -18.15M | 712K | 18.15M |
Working Capital Changes | 671K | 19.36M | 2.33M | 5.34M | 9.82M | 61.13M | -14.56M | -200K | -80.64M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -15M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 780K | 436K | 5.75M | 6.04M | 18.32M | 1.77M | 35.18M | 3.73M | 16.67M |
Cash from Investing | -49K | -235K | -7.79M | -82.52M | -189.96M | -130.07M | -854.2M | -1.45M | -405.42M |
Capital Expenditures | -49K | -235K | -1.09M | -3.74M | -2.82M | -4.23M | -7.07M | -1.45M | -7.03M |
CapEx % of Revenue | 12.93% | 10.13% | 16.09% | 40.1% | 30.6% | 44.23% | 64.84% | 7.76% | 19.1% |
Acquisitions | 0 | 0 | 0 | 82.52M | 187.13M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | -82.52M | -187.13M | 0 | 0 | 0 | -3.17M |
Cash from Financing | 5.14M | 89.23M | 272.04M | 176.32M | 346.17M | 93.86M | 1.19B | 42.57M | 1.18B |
Debt Issued (Net) | 4.98M | 16.65M | -4.68M | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 72.62M | 276.25M | 174.68M | 344.78M | 91.74M | 1B | 0 | 841.19M |
Dividends Paid | 0 | -106K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 162K | 65K | 466K | 1.64M | 1.39M | 2.13M | 191.81M | 42.57M | 334.58M |
Net Change in Cash | -4.56M▲ 0% | 91.49M▲ 2106.3% | 227.13M▲ 148.3% | -1.01M▼ 100.4% | 19.95M▲ 2067.3% | -155.27M▼ 878.4% | 37.29M▲ 124.0% | 0▼ 100.0% | 363.81M▲ 0% |
Free Cash Flow | -9.7M▲ 0% | 2.25M▲ 123.2% | -38.21M▼ 1794.4% | -98.55M▼ 157.9% | -139.09M▼ 41.1% | -123.29M▲ 11.4% | -307.94M▼ 149.8% | -42.57M▲ 86.2% | -416.44M▲ 0% |
FCF Margin % | -2560.42% | 97.24% | -562.97% | -1056.76% | -1507.92% | -1289.67% | -2825.88% | -228.67% | -1131.14% |
FCF Growth % | - | 123.24% | -1794.41% | -157.93% | -41.13% | 11.36% | -149.76% | 86.17% | -14.02% |
FCF per Share | -0.47 | 0.06 | -1.76 | -2.38 | -2.67 | -1.69 | -2.76 | -2.49 | -24.35 |
FCF Conversion (FCF/Net Income) | 0.81x | -0.10x | 0.84x | 0.80x | 0.78x | 0.56x | 0.93x | 0.54x | 1.05x |
Interest Paid | 0 | 322K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RNA Key Ratios
Atrium Therapeutics, Inc. (RNA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -36.83% | -34.32% | -36.27% | -39.34% | -33.47% | -9.4% | -85.86% |
| Return on Invested Capital (ROIC) | - | - | -303.16% | -83.58% | -61.58% | -36.97% | -9.99% | -157.33% |
| Gross Margin | 100% | -454.03% | -984.95% | 84.96% | 78.02% | 100% | 100% | -275.59% |
| Net Margin | -1066.58% | -653.53% | -1265.38% | -1886.33% | -2219.87% | -2957.71% | -411.88% | -1076.87% |
| Debt / Equity | - | 0.00x | 0.03x | 0.02x | 0.02x | 0.00x | 0.02x | 0.01x |
| Interest Coverage | -2.35x | -211.22x | - | - | - | - | - | - |
| FCF Conversion | -0.10x | 0.84x | 0.80x | 0.78x | 0.56x | 0.93x | 0.54x | 1.05x |
| Revenue Growth | 511.87% | 192.67% | 37.41% | -1.09% | 3.64% | 13.99% | 70.85% | 312.41% |
Related:RNA Dividend History·RNA Revenue History·RNA Price History·RNA P/E History·RNA Financial Ratios·RNA Institutional Holders
RNA SEC Filings & Documents
Atrium Therapeutics, Inc. (RNA) SEC filings — annual & quarterly reports (10-K, 10-Q)
RNA Frequently Asked Questions
Atrium Therapeutics, Inc. (RNA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Atrium Therapeutics, Inc. (RNA) reported $36.8M in revenue for fiscal year 2025. This represents a 9614% increase from $0.4M in 2018.
Atrium Therapeutics, Inc. (RNA) grew revenue by 70.9% over the past year. This is strong growth.
Atrium Therapeutics, Inc. (RNA) reported a net loss of $396.5M for fiscal year 2025.
Dividend & Returns
Atrium Therapeutics, Inc. (RNA) has a return on equity (ROE) of -9.4%. Negative ROE indicates the company is unprofitable.
Atrium Therapeutics, Inc. (RNA) had negative free cash flow of $416.4M in fiscal year 2025, likely due to heavy capital investments.